BMO Capital analyst Gary Nachman raised his price target on Endo to $16 after its "impressive" Q2 results, saying the company appears to have found its footing. The analyst notes the "significant improvement" in Endo's gross margins was a "positive surprise", adding that its legacy generics business is stabilizing while its key growth drivers performed strongly. Nachman also keeps his Market Perform rating on Endo given the company's modest growth outlook and limited cash flow generation, also stating that the stock price has "substantially rebased" and its leverage remains high.